Gene Silencing News and Research

RSS

Sigma-Aldrich licenses RNAi patent estate from Alnylam

Sigma-Aldrich Corporation and Alnylam Pharmaceuticals announced today that Alnylam has granted Sigma-Aldrich a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family.

19 Jul 2005

Research shows how a virus uses the gene silencing machinery for its own infectious purposes

In the latest version of the hide-and-seek game between pathogens and the hosts they infect, researchers have found that a virus appears to cloak itself with a recently discovered gene silencing device to evade detection and destruction by immune cells.

3 Jun 2005

Bionomics files key U.S. patents relating to cancer drug target BNO69

Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.

9 May 2005

Research helps understand how the malaria parasite disguises itself to avoid detection by the immune system

Scientists are making strides in understanding how the malaria parasite Plasmodium falciparum disguises itself to avoid detection by the immune system. The findings could lead to the development of new drugs for a disease that causes more than 300 million acute illnesses and at least one million deaths each year, most of them in developing countries.

7 Apr 2005

Research tool for turning off genes may eventually have therapeutic application

A research team based at Massachusetts General Hospital (MGH) has identified 80 new genes essential to the process of RNA interference (RNAi), a powerful new research tool for inactivating genes in plants or animals.

28 Mar 2005

RNA interference as promising therapy for ALS

Scientists at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have used RNA interference in transgenic mice to silence a mutated gene that causes inherited cases of amytrophic lateral sclerosis (ALS), substantially delaying both the onset and the progression rate of the fatal motor neuron disease.

13 Mar 2005

Discovery of a protein JBP2, an important tool for African sleeping sickness research

Sixty million people in 36 countries of sub-Saharan Africa are threatened daily by a deadly parasitic disease known as African sleeping sickness.

28 Feb 2005

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Gene silencing may provide hope for leukemia sufferers

Ever since the approval of Gleevec in 2001, a cancer-cell-specific drug used to treat chronic myelogenous leukemia (CML), the field of cancer therapeutics has been rushing full speed into the era of so-called "targeted" medicines.

1 Nov 2004

Advances in gene silencing on the agenda

Recent advances in using 'RNA interference' (RNAi) to improve plant, animal and human health will be the major focus of the CSIRO-hosted Horizons in Livestock Sciences Conference on the Gold Coast from 12-15 September.

8 Sep 2004

New genetic hypothesis for the cause of autism

Researchers have proposed a new hypothesis on the cause of autism, suggesting a mixed epigenetic and genetic and mixed de novo and inherited (MEGDI) model.

8 Sep 2004

Bionomics BNO69 angiogenesis gene discovery published

Bionomics has announced that research conducted by Bionomics and its collaborators at the Hanson Centre of the Institute of Medical and Veterinary Science ("IMVS") in Adelaide, Australia, relating to Bionomics' proprietary angiogenesis drug target BNO69, has been published in the high ranking scientific journal Proceedings of the National Academy of Sciences USA (PNAS).

10 Aug 2004

New gene-silencing technique

A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.

5 Aug 2004

Entirely new approach to the treatment of aging

Dispelling the belief that the only way to treat such conditions is by fixing or replacing damaged genes, they instead focused on the field of epigenetics—the study of changes in gene silencing that occur without changes in the genes themselves.

3 Aug 2004

Market research 'World RNAi Markets: Current and Future Outlook'

Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.

19 Jul 2004

Gene therapy may provide a treatment for a group of incurable, progressive neurological diseases called polyglutamine-repeat diseases

Researchers from the University of Iowa have have shown for the first time that gene therapy delivered to the brains of living mice can prevent the physical symptoms and neurological damage caused by an inherited neurodegenerative disease that is similar to Huntington's disease (HD).

5 Jul 2004

Lou Gehrig's disease may be treated or even prevented

Tripping, stumbling, falling, slow, steady loss of muscle control and strength in hands and feet, difficulty speaking, swallowing and breathing...

28 Jun 2004

Australia's CSIRO to exhibit major display at the world's largest biotechnology conference

CSIRO is mounting a major display of technologies this week at BIO 2004, the world's largest biotechnology conference, being held in San Francisco, USA, from 6-9 June.

7 Jun 2004

Novel molecular targeting technologies to deliver gene-silencing therapy

Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier.

1 Jun 2004

QIAGEN launches human siRNA library sets

Prime Standard QIA a leading supplier of products and technologies for nucleic acid separation, purification and handling today announced that it has launched a series of off-the-shelf human library siRNA sets, covering a broad gene family selection including kinases, GPCRs, apoptosis related genes, and oncogenes, to name a few.

From QIAGEN Manchester Limited 3 May 2004